The Trump administration on Thursday unveiled its final rule allowing states to import some prescription drugs from Canada.
The rule allows states and, under some circumstances, pharmacists or wholesale distributors to import drugs from Canada if their plan wouldn’t pose additional safety risks to the public and would save consumers a significant amount of money. The Food and Drug Administration would have to approve each plan. The rule goes into effect 60 days after it is published in the Federal Register.
According to the rule, HHS was unable to estimate the rule’s cost savings because it didn’t have information about the likely size and scope of state importation plans, which drugs would be included, how much those drugs would cost or which domestic drugmakers make eligible drugs.
It also includes legal language that would essentially put an end to the program if a court struck down any part of it.
“The provisions of this part are not separate and are not severable from one another. If any provision is stayed or determined to be invalid or unenforceable, the remaining provisions shall not continue in effect,” the rule says.